GSK press releases Follow Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease (COPD) Nucala is the only monthly biologic studied in a wide COPD population with an eosinophilic phenotype. https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-receives-positive-chmp-opinion-for-treatment-of-chronic-obstructive-pulmonary-disease/ gsk.com
